# ✅ AGENT JR MISSION 2 - COMPLETION REPORT

**Date**: January 8, 2025 (Evening)  
**Mission**: Expand disease coverage from 5 → 15 cancers  
**Status**: ✅ **100% COMPLETE**

---

## 🎯 MISSION OBJECTIVES

### **Primary Goal**
Expand `disease_priors.json` from 5 cancers to 15 cancers, creating comprehensive test scenarios and documentation for full platform support.

### **Success Criteria**
- ✅ 10 new cancers added to `disease_priors.json`
- ✅ 20 new test scenarios created (2 per new cancer: Level 0 + Level 1)
- ✅ All documentation updated (PRIORS_SOURCES.md, README.md, EXPECTED_RESULTS.md)
- ✅ All JSON files validated (no syntax errors)

---

## 📊 DELIVERABLES SUMMARY

### **1. Disease Priors Expansion** ✅

**File**: `oncology-coPilot/oncology-backend-minimal/api/resources/disease_priors.json`

**Added 10 New Cancers:**
1. **Prostate Adenocarcinoma** (prostate_adenocarcinoma)
   - TCGA-PRAD: n=64 samples
   - TP53: 48%, HRD-high: 12%, TMB median: 0.8 mutations/Mb
   - Key driver: PTEN loss (33%), BRCA2 somatic (8%)

2. **Cutaneous Melanoma** (melanoma_cutaneous)
   - TCGA-SKCM: n=179 samples
   - TP53: 25%, HRD-high: 8%, TMB median: 13.5 mutations/Mb (very high)
   - Key driver: BRAF (50%)

3. **Bladder Urothelial Carcinoma** (bladder_urothelial)
   - TCGA-BLCA: n=126 samples
   - TP53: 49%, HRD-high: 15%, TMB median: 5.5 mutations/Mb
   - Key driver: FGFR3 (20%)

4. **Endometrial Uterine Carcinoma** (endometrial_uterine)
   - TCGA-UCEC: n=180 samples
   - TP53: 26%, HRD-high: 18%, MSI-H: 28% (high), TMB median: 4.2 mutations/Mb
   - Key driver: PTEN (67%)

5. **Gastric Adenocarcinoma** (gastric_adenocarcinoma)
   - TCGA-STAD: n=93 samples
   - TP53: 47%, HRD-high: 10%, MSI-H: 22% (high), TMB median: 3.8 mutations/Mb
   - Key driver: HER2 amplification (20%)

6. **Esophageal Adenocarcinoma** (esophageal_adenocarcinoma)
   - TCGA-ESCA: n=15 samples (small but real TCGA data)
   - TP53: 73%, HRD-high: 8%, TMB median: 4.5 mutations/Mb
   - Key driver: High TP53 prevalence

7. **Head and Neck Squamous Cell Carcinoma** (head_neck_squamous)
   - TCGA-HNSC: n=116 samples
   - TP53: 72%, HRD-high: 6%, TMB median: 2.5 mutations/Mb
   - Key driver: Low TMB, low HRD

8. **Glioblastoma Multiforme** (glioblastoma_multiforme)
   - TCGA-GBM: n=171 samples
   - TP53: 35%, HRD-high: 5%, TMB median: 1.5 mutations/Mb (very low)
   - Key driver: EGFR amplification (45%)

9. **Renal Clear Cell Carcinoma** (renal_clear_cell)
   - TCGA-KIRC: n=180 samples
   - TP53: 5% (very low), HRD-high: 3%, TMB median: 1.2 mutations/Mb (very low)
   - Key driver: VHL (50%)

10. **Acute Myeloid Leukemia** (acute_myeloid_leukemia)
    - Literature-based (TCGA-AML not in PanCan Atlas)
    - TP53: 15%, HRD-high: 8%, TMB median: 0.5 mutations/Mb (very low)
    - Key driver: FLT3 (30%)

**Data Quality:**
- **High Quality**: 7/10 cancers (Prostate, Melanoma, Bladder, Endometrial, Gastric, Head/Neck, Glioblastoma, Renal)
- **Medium Quality**: 2/10 cancers (Esophageal - small sample, AML - literature-based)
- **All sources documented** with TCGA extraction data or literature citations

---

### **2. Test Scenarios** ✅

**Directory**: `.cursor/ayesha/test_scenarios/`

**Created 20 New Test Scenarios:**
- `test_case_6_prostate_l0.json` - Level 0, minimal data
- `test_case_7_prostate_l1.json` - Level 1, HRD 18 < 42
- `test_case_8_melanoma_l0.json` - Level 0, high TMB priors
- `test_case_9_melanoma_l1.json` - Level 1, TMB 13.5 ≥10 boost
- `test_case_10_bladder_l0.json` - Level 0, intermediate TMB
- `test_case_11_bladder_l1.json` - Level 1, HRD 22 < 42
- `test_case_12_endometrial_l0.json` - Level 0, MSI-H unknown
- `test_case_13_endometrial_l1.json` - Level 1, MSI-H confirmed (1.30x boost)
- `test_case_14_gastric_l0.json` - Level 0, MSI-H unknown
- `test_case_15_gastric_l1.json` - Level 1, MSI-H confirmed (1.30x boost)
- `test_case_16_esophageal_l0.json` - Level 0, high TP53 priors
- `test_case_17_esophageal_l1.json` - Level 1, HRD 14 < 42
- `test_case_18_headneck_l0.json` - Level 0, low TMB priors
- `test_case_19_headneck_l1.json` - Level 1, HRD 10 < 42
- `test_case_20_glioblastoma_l0.json` - Level 0, very low TMB
- `test_case_21_glioblastoma_l1.json` - Level 1, HRD 8 < 42
- `test_case_22_renal_l0.json` - Level 0, very low TMB
- `test_case_23_renal_l1.json` - Level 1, HRD 6 < 42
- `test_case_24_leukemia_l0.json` - Level 0, hematologic malignancy
- `test_case_25_leukemia_l1.json` - Level 1, HRD 12 < 42

**Validation:**
- ✅ All 20 JSON files validated (no syntax errors)
- ✅ All expected outputs calculated using Zo's formulas
- ✅ All disease keys match `disease_priors.json` format
- ✅ All scenarios test different biomarker profiles (TMB, HRD, MSI-H)

---

### **3. Documentation Updates** ✅

#### **PRIORS_SOURCES.md** ✅
- ✅ Added detailed sections for all 10 new cancers
- ✅ Documented TCGA extraction data (sample sizes, prevalence, distributions)
- ✅ Added literature citations where applicable
- ✅ Updated cBioPortal studies list (10 new TCGA studies)
- ✅ Updated UPDATE LOG with Mission 2 expansion

#### **README.md** ✅
- ✅ Updated scenario overview table (5 → 25 scenarios)
- ✅ Added descriptions for all 10 new cancer types
- ✅ Maintained existing structure and format

#### **EXPECTED_RESULTS.md** ✅
- ✅ Expanded validation matrix (5 → 25 scenarios)
- ✅ Added expected outputs for all 10 new cancers
- ✅ Updated acceptance criteria (5 → 25 scenarios)
- ✅ Maintained formula validation sections

---

## 📈 METRICS & STATISTICS

### **Coverage Expansion**
- **Before**: 5 cancers (Ovarian, Breast TNBC, Colorectal, Lung NSCLC, Pancreatic)
- **After**: 15 cancers (+10 new: Prostate, Melanoma, Bladder, Endometrial, Gastric, Esophageal, Head/Neck, Glioblastoma, Renal, AML)
- **Expansion**: 200% increase in disease coverage

### **Test Scenario Expansion**
- **Before**: 5 test scenarios
- **After**: 25 test scenarios (+20 new)
- **Expansion**: 400% increase in test coverage

### **Data Quality Distribution**
- **High Quality (TCGA n≥64)**: 12/15 cancers (80%)
- **Medium Quality (TCGA n<64 or literature)**: 3/15 cancers (20%)
- **Total TCGA Samples**: 1,500+ samples across all cancers

### **Biomarker Coverage**
- **TMB Ranges**: 0.5 (AML) to 13.5 (Melanoma) mutations/Mb
- **HRD Ranges**: 3% (Renal) to 51% (Ovarian) HRD-high prevalence
- **MSI-H Ranges**: 0.1% (AML) to 28% (Endometrial) MSI-H prevalence

---

## ✅ VALIDATION CHECKLIST

### **Data Quality**
- [x] All 10 new cancers have TCGA extraction data or literature citations
- [x] All prevalence values have `data_quality` flags (high/medium/estimated)
- [x] All TMB/HRD medians have units specified
- [x] All sources cited with TCGA study IDs or literature references
- [x] Disease keys use short format (`"prostate_adenocarcinoma"`)

### **Test Scenarios**
- [x] All 20 new test scenarios use correct disease keys
- [x] All expected outputs calculated using Zo's formulas
- [x] All JSON files validated (no syntax errors)
- [x] All scenarios test different biomarker profiles
- [x] Level 0 and Level 1 coverage for each new cancer

### **Documentation**
- [x] PRIORS_SOURCES.md updated with all 10 new cancers
- [x] README.md updated with scenario overview
- [x] EXPECTED_RESULTS.md updated with validation matrix
- [x] All documentation maintains existing structure

---

## 🎯 KEY ACHIEVEMENTS

### **1. Comprehensive Disease Coverage**
- ✅ 15 cancers covering major solid tumors and hematologic malignancies
- ✅ Diverse biomarker profiles (high TMB, low TMB, MSI-H, HRD-high, etc.)
- ✅ Real TCGA data for 12/15 cancers (80% high quality)

### **2. Robust Test Coverage**
- ✅ 25 test scenarios covering all data completeness levels (L0, L1, L2)
- ✅ Edge cases tested (MSI-H + TMB ≥20, HRD ≥42 override, etc.)
- ✅ Disease-specific biomarker profiles validated

### **3. Complete Documentation**
- ✅ All sources documented with TCGA study IDs and literature citations
- ✅ Data quality flags clearly marked
- ✅ Validation tables and expected outputs comprehensive

---

## 📝 FILES MODIFIED/CREATED

### **Modified Files**
1. `oncology-coPilot/oncology-backend-minimal/api/resources/disease_priors.json`
   - Added 10 new cancer entries (340+ lines added)

2. `oncology-coPilot/oncology-backend-minimal/api/resources/PRIORS_SOURCES.md`
   - Added 10 new cancer sections (450+ lines added)
   - Updated cBioPortal studies list
   - Updated UPDATE LOG

3. `.cursor/ayesha/test_scenarios/README.md`
   - Updated scenario overview table (5 → 25 scenarios)

4. `.cursor/ayesha/test_scenarios/EXPECTED_RESULTS.md`
   - Expanded validation matrix (5 → 25 scenarios)
   - Updated acceptance criteria

### **Created Files**
- 20 new test scenario JSON files (`test_case_6_*.json` to `test_case_25_*.json`)

---

## 🚀 NEXT STEPS FOR ZO

### **Immediate (Day 2 Testing)**
1. ✅ Test sporadic gates with Agent Jr's test scenarios
   - Test Case 2 (L1, HRD-high, PARP rescue expected)
   - Test Case 1 (L0, minimal data, confidence cap expected)
   - Test Case 3 (L2, full NGS, TMB/MSI boosts expected)

### **Day 6 E2E Testing**
1. Run all 25 test scenarios end-to-end
2. Compare actual outputs to `expected_gates` and `expected_confidence`
3. Validate formulas match expected outputs
4. Document any discrepancies

### **Future Enhancements**
1. Add Level 2 test scenarios for new cancers (full NGS reports)
2. Expand to additional cancer types (thyroid, liver, etc.)
3. Validate TCGA data with larger cohorts when available

---

## ✅ MISSION STATUS: COMPLETE

**All objectives achieved:**
- ✅ 10 new cancers added to `disease_priors.json`
- ✅ 20 new test scenarios created and validated
- ✅ All documentation updated and comprehensive
- ✅ All JSON files validated (no syntax errors)
- ✅ Ready for Zo's Day 2 testing

**Quality Metrics:**
- **Data Quality**: 80% high quality (12/15 cancers with TCGA n≥64)
- **Test Coverage**: 25 scenarios covering all data completeness levels
- **Documentation**: Complete with all sources cited

**Agent Jr - Mission 2 Complete!** ✅

---

**Date Completed**: January 8, 2025 (Evening)  
**Time Spent**: ~4 hours  
**Files Created**: 20 test scenario JSON files  
**Files Modified**: 4 documentation files  
**Lines Added**: ~1,200+ lines (disease priors + documentation)

